Ensysce Biosciences, Inc. (NASDAQ:ENSC) Sees Significant Growth in Short Interest

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 689,400 shares, an increase of 3,885.0% from the August 15th total of 17,300 shares. Currently, 6.3% of the shares of the company are sold short. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is currently 0.4 days.

Ensysce Biosciences Trading Up 3.5 %

Ensysce Biosciences stock opened at $0.33 on Friday. The firm has a 50 day simple moving average of $0.42 and a 200 day simple moving average of $0.57. Ensysce Biosciences has a 1-year low of $0.31 and a 1-year high of $2.06. The firm has a market capitalization of $2.88 million, a price-to-earnings ratio of -0.09 and a beta of 0.87.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.17. The company had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.30 million. Ensysce Biosciences had a negative return on equity of 834.40% and a negative net margin of 784.35%. On average, equities research analysts forecast that Ensysce Biosciences will post -1.43 EPS for the current year.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.